Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -35.38
- Piotroski Score 3.00
- Grade Neutral
- Symbol (BCEL)
- Company Atreca, Inc.
- Price $0.09
- Changes Percentage (-1.32%)
- Change -$0
- Day Low $0.09
- Day High $0.09
- Year High $1.20
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 06/17/2024
- Fiscal Year End N/A
- Average Stock Price Target $4.00
- High Stock Price Target $4.00
- Low Stock Price Target $4.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.50
- Trailing P/E Ratio -0.04
- Forward P/E Ratio -0.04
- P/E Growth -0.04
- Net Income $-90,525,000
Income Statement
Quarterly
Annual
Latest News of BCEL
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript
AbCellera provided updates on their pipeline progress and financials, emphasizing their transition to a clinical stage biotech company. They anticipate CTA filings for two programs in Q2 next year. Th...
By Yahoo! Finance | 17 hours ago -
AbCellera Biologics Inc. (ABCL): The Best Multibagger Penny Stock of 2025?
A list of the top multibagger penny stocks for 2025 was compiled, with AbCellera Biologics Inc. being a standout. The term multibagger refers to stocks that can increase substantially....
By Yahoo! Finance | 2 months ago
